CIK 0001159036 · Large accelerated filer
HALOZYME THERAPEUTICS, INC.
Sign in to watch- Ticker
- HALO
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 880488686
- Phone
- (858) 794-8889
- Business address
- 12390 EL CAMINO REAL, SAN DIEGO, CA, 92130
- Former names
- HALOZYME THERAPEUTICS INC, GLOBAL YACHT SERVICES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $19,884,955
- in 5 filings, $19.9M under 10b5-1 plans
Net −$19,884,955. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-09 | Torley Helen PRESIDENT AND CEO | Grant or award · Performance Stock Units | +19,807 | 51,171 | ||
| 2026-02-09 | Torley Helen PRESIDENT AND CEO | Grant or award · Performance Stock Units | +24,985 | 144,400 | ||
| 2026-02-09 | Torley Helen PRESIDENT AND CEO | Grant or award · Performance Stock Units | +92,714 | 92,714 | ||
| 2026-02-05 | Torley Helen PRESIDENT AND CEO | Option exercise 10b5-1 | +10,000 | $12.07 | $121K | 718,719 |
| 2026-02-05 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 | −5,376 | $78.38 | $421K | 713,343 |
| 2026-02-05 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 | −4,624 | $78.94 | $365K | 708,719 |
| 2026-02-05 | Torley Helen PRESIDENT AND CEO | Option exercise · Option to Purchase Common Stock 10b5-1 | −10,000 | $12.07 | $121K | 201,923 |
| 2026-02-04 | Torley Helen PRESIDENT AND CEO | Option exercise 10b5-1 | +20,000 | $12.07 | $241K | 728,719 |
| 2026-02-04 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 | −9,900 | $76.94 | $762K | 718,819 |
| 2026-02-04 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 | −10,100 | $77.54 | $783K | 708,719 |
| 2026-02-04 | Torley Helen PRESIDENT AND CEO | Option exercise · Option to Purchase Common Stock 10b5-1 | −20,000 | $12.07 | $241K | 211,923 |
| 2026-02-03 | Torley Helen PRESIDENT AND CEO | Option exercise 10b5-1 | +20,000 | $12.07 | $241K | 728,719 |
| 2026-02-03 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 | −2,551 | $74.88 | $191K | 726,168 |
| 2026-02-03 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 | −9,659 | $75.94 | $734K | 716,509 |
| 2026-02-03 | Torley Helen PRESIDENT AND CEO | Sale 10b5-1 | −7,790 | $76.73 | $598K | 708,719 |
| 2026-02-03 | Torley Helen PRESIDENT AND CEO | Option exercise · Option to Purchase Common Stock 10b5-1 | −20,000 | $12.07 | $241K | 231,923 |
| 2026-01-05 | Connaughton Bernadette Director | Sale 10b5-1 | −2,000 | $70.25 | $141K | 40,123 |
| 2026-01-03 | Snyder Mark Howard SVP, CHIEF LEGAL OFFICER | Option exercise | +7,611 | 38,424 | ||
| 2026-01-03 | Snyder Mark Howard SVP, CHIEF LEGAL OFFICER | Shares withheld for taxes | −4,243 | $70.31 | $298K | 34,181 |
| 2026-01-03 | Snyder Mark Howard SVP, CHIEF LEGAL OFFICER | Option exercise · Restricted Stock Units | −7,611 | 0 |
Page 12 of 26 · 513 trades